Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus

Directly acting antivirals recently have become available for the treatment of hepatitis C virus (HCV) infection, but there is no prophylactic vaccine for HCV. In the present study, we took advantage of the properties of Japanese encephalitis virus (JEV) to develop antigens for use in a HCV vaccine....

Descripción completa

Detalles Bibliográficos
Autores principales: Saga, Ryohei, Fujimoto, Akira, Watanabe, Noriyuki, Matsuda, Mami, Hasegawa, Makoto, Watashi, Koichi, Aizaki, Hideki, Nakamura, Noriko, Tajima, Shigeru, Takasaki, Tomohiko, Konishi, Eiji, Kato, Takanobu, Kohara, Michinori, Takeyama, Haruko, Wakita, Takaji, Suzuki, Ryosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922013/
https://www.ncbi.nlm.nih.gov/pubmed/27345289
http://dx.doi.org/10.1038/srep28688

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922013/
https://www.ncbi.nlm.nih.gov/pubmed/27345289
http://dx.doi.org/10.1038/srep28688

Ejemplares similares